{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T08:39:45Z","timestamp":1789893585045,"version":"4.0.1"},"reference-count":59,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","onlinecjc.ca","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.cjca.2014.04.014","type":"journal-article","created":{"date-parts":[[2014,4,18]],"date-time":"2014-04-18T09:19:14Z","timestamp":1397812754000},"page":"1233-1240","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Riociguat: A Novel Therapeutic Option for Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension"],"prefix":"10.1016","volume":"30","author":[{"given":"Lisa M.","family":"Mielniczuk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Swiston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjca.2014.04.014_bib1","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1161\/CIRCULATIONAHA.109.192230","volume":"119","author":"McLaughlin","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2014.04.014_bib2","doi-asserted-by":"crossref","first-page":"13S","DOI":"10.1016\/j.jacc.2004.02.029","article-title":"Cellular and molecular pathobiology of pulmonary arterial hypertension","volume":"43","author":"Humbert","year":"2004","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2014.04.014_bib3","doi-asserted-by":"crossref","first-page":"4306","DOI":"10.1172\/JCI60658","article-title":"Molecular pathogenesis of pulmonary arterial hypertension","volume":"122","author":"Rabinovitch","year":"2012","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.cjca.2014.04.014_bib4","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1161\/01.CIR.0000102381.57477.50","article-title":"Endothelial dysfunction in pulmonary hypertension","volume":"109","author":"Budhiraja","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2014.04.014_bib5","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/S0005-2728(99)00024-9","article-title":"Guanylate cyclase and the.NO\/cGMP signaling pathway","volume":"1411","author":"Denninger","year":"1999","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.cjca.2014.04.014_bib6","doi-asserted-by":"crossref","first-page":"68S","DOI":"10.1016\/j.jacc.2004.02.031","article-title":"Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension","volume":"43","author":"Ghofrani","year":"2004","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2014.04.014_bib7","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1164\/rccm.200412-1684OC","article-title":"Decreased exhaled nitric oxide in pulmonary arterial hypertension: response to bosentan therapy","volume":"172","author":"Girgis","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.cjca.2014.04.014_bib8","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1378\/chest.111.1.44","article-title":"Exhaled nitric oxide during exercise in primary pulmonary hypertension and pulmonary fibrosis","volume":"111","author":"Riley","year":"1997","journal-title":"Chest"},{"key":"10.1016\/j.cjca.2014.04.014_bib9","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/978-3-642-38664-0_12","article-title":"Soluble guanylate cyclase stimulators in pulmonary hypertension","volume":"218","author":"Stasch","year":"2013","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.cjca.2014.04.014_bib10","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1183\/09059180.00004812","article-title":"Pathways in pulmonary arterial hypertension: the future is here","volume":"21","author":"Sitbon","year":"2012","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.cjca.2014.04.014_bib11","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1517\/14656566.2011.564159","article-title":"Endothelin receptor antagonists for the treatment of pulmonary arterial hypertension","volume":"12","author":"O'Callaghan","year":"2011","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.cjca.2014.04.014_bib12","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1183\/09031936.00039808","article-title":"First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension","volume":"33","author":"Grimminger","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1016\/j.cjca.2014.04.014_bib13","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1161\/CIRCULATIONAHA.110.981738","article-title":"Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease","volume":"123","author":"Stasch","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2014.04.014_bib14","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1183\/09031936.00114407","article-title":"Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension","volume":"32","author":"Schermuly","year":"2008","journal-title":"Eur Respir J"},{"key":"10.1016\/j.cjca.2014.04.014_bib15","unstructured":"Adempas Product Monograph. Bayer Inc, Toronto, Ontario, Canada. September 17, 2013. Available at: http:\/\/labeling.bayerhealthcare.com\/html\/products\/pi\/Adempas_PI.pdf. Accessed April 25,\u00a02014."},{"key":"10.1016\/j.cjca.2014.04.014_bib16","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1177\/0091270010378119","article-title":"Riociguat (BAY 63-2521) and warfarin: a pharmacodynamic and pharmacokinetic interaction study","volume":"51","author":"Frey","year":"2011","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.cjca.2014.04.014_bib17","doi-asserted-by":"crossref","first-page":"D51","DOI":"10.1016\/j.jacc.2013.10.023","article-title":"Pulmonary arterial hypertension: epidemiology and registries","volume":"62","author":"McGoon","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2014.04.014_bib18","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1378\/chest.11-1460","article-title":"An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry","volume":"142","author":"Benza","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.cjca.2014.04.014_bib19","doi-asserted-by":"crossref","first-page":"343","DOI":"10.7326\/0003-4819-115-5-343","article-title":"Survival in patients with primary pulmonary hypertension. Results from a national prospective registry","volume":"115","author":"D'Alonzo","year":"1991","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cjca.2014.04.014_bib20","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1378\/chest.10-2327","article-title":"Survival of Chinese patients with pulmonary arterial hypertension in the modern treatment era","volume":"140","author":"Zhang","year":"2011","journal-title":"Chest"},{"key":"10.1016\/j.cjca.2014.04.014_bib21","doi-asserted-by":"crossref","first-page":"D4","DOI":"10.1016\/j.jacc.2013.10.025","article-title":"Relevant issues in the pathology and pathobiology of pulmonary hypertension","volume":"62","author":"Tuder","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2014.04.014_bib22","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1007\/s11906-013-0394-8","article-title":"An update on medical therapy for pulmonary arterial hypertension","volume":"15","author":"Wu","year":"2013","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.cjca.2014.04.014_bib23","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ejcts.2010.02.039","article-title":"Long-term outcome of double-lung and heart-lung transplantation for pulmonary hypertension: a comparative retrospective study of 219 patients","volume":"38","author":"Fadel","year":"2010","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.cjca.2014.04.014_bib24","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1056\/NEJM199507273330403","article-title":"Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension","volume":"333","author":"Giaid","year":"1995","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2014.04.014_bib25","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/S0003-4975(96)00542-5","article-title":"Rebound pulmonary hypertension after inhalation of nitric oxide","volume":"62","author":"Atz","year":"1996","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.cjca.2014.04.014_bib26","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1161\/CIRCULATIONAHA.108.839274","article-title":"Tadalafil therapy for pulmonary arterial hypertension","volume":"119","author":"Galie","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2014.04.014_bib27","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMoa050010","article-title":"Sildenafil citrate therapy for pulmonary arterial hypertension","volume":"353","author":"Galie","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2014.04.014_bib28","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.jacc.2012.05.004","article-title":"Tadalafil for the treatment of pulmonary arterial hypertension: a double-blind 52-week uncontrolled extension study","volume":"60","author":"Oudiz","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2014.04.014_bib29","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1378\/chest.10-0969","article-title":"Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study","volume":"140","author":"Rubin","year":"2011","journal-title":"Chest"},{"key":"10.1016\/j.cjca.2014.04.014_bib30","doi-asserted-by":"crossref","first-page":"D60","DOI":"10.1016\/j.jacc.2013.10.031","article-title":"Updated treatment algorithm of pulmonary arterial hypertension","volume":"62","author":"Galie","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2014.04.014_bib31","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1183\/09031936.00182909","article-title":"Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study","volume":"36","author":"Ghofrani","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.cjca.2014.04.014_bib32","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1209655","article-title":"Riociguat for the treatment of pulmonary arterial hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2014.04.014_bib33","doi-asserted-by":"crossref","unstructured":"Rubin L, Nazzareno G, Grimminger F, et\u00a0al. Riociguat for the treatment of pulmonary arterial hypertension (PAH): 1-year results from the PATENT-2 long-term extension study. Paper presented at CHEST 2013. October 26-31, 2013. Chicago, IL.","DOI":"10.1378\/chest.1783307"},{"key":"10.1016\/j.cjca.2014.04.014_bib34","volume":"187","author":"Nazzareno","year":"2013","journal-title":"Clinical trials in pulmonary hypertension Am J Respir Crit Care Med"},{"key":"10.1016\/j.cjca.2014.04.014_bib35","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1183\/09059180.00009211","article-title":"State-of-the-art chronic thromboembolic pulmonary hypertension diagnosis and management","volume":"21","author":"Jenkins","year":"2012","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.cjca.2014.04.014_bib36","first-page":"301","article-title":"Diagnostic evaluation and management of chronic thromboembolic pulmonary hypertension: a clinical practice guideline","volume":"17","author":"Mehta","year":"2010","journal-title":"Can Respir J"},{"key":"10.1016\/j.cjca.2014.04.014_bib37","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1378\/chest.81.2.151","article-title":"Longterm follow-up of patients with pulmonary thromboembolism. Late prognosis and evolution of hemodynamic and respiratory data","volume":"81","author":"Riedel","year":"1982","journal-title":"Chest"},{"key":"10.1016\/j.cjca.2014.04.014_bib38","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1378\/chest.119.3.818","article-title":"Prognostic factors in medically treated patients with chronic pulmonary embolism","volume":"119","author":"Lewczuk","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.cjca.2014.04.014_bib39","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1183\/09031936.00058112","article-title":"Surgical treatment of chronic thromboembolic pulmonary hypertension","volume":"41","author":"Jenkins","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1016\/j.cjca.2014.04.014_bib40","doi-asserted-by":"crossref","first-page":"D92","DOI":"10.1016\/j.jacc.2013.10.024","article-title":"Chronic thromboembolic pulmonary hypertension","volume":"62","author":"Kim","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2014.04.014_bib41","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.athoracsur.2012.04.004","article-title":"Pulmonary endarterectomy: recent changes in a single institution's experience of more than 2,700 patients","volume":"94","author":"Madani","year":"2012","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.cjca.2014.04.014_bib42","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.jtcvs.2010.11.024","article-title":"Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry","volume":"141","author":"Mayer","year":"2011","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.cjca.2014.04.014_bib43","volume":"187","author":"Gerald","year":"2013","journal-title":"Am J Resepir Crit Care Med"},{"key":"10.1016\/j.cjca.2014.04.014_bib44","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1183\/09059180.00007409","article-title":"Surgical and post-operative treatment of chronic thromboembolic pulmonary hypertension","volume":"19","author":"Mayer","year":"2010","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.cjca.2014.04.014_bib45","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1183\/09031936.00201612","article-title":"Chronic thromboembolic pulmonary hypertension: role of medical therapy","volume":"41","author":"Pepke-Zaba","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1016\/j.cjca.2014.04.014_bib46","doi-asserted-by":"crossref","first-page":"e419S","DOI":"10.1378\/chest.11-2301","article-title":"Antithrombotic therapy for VTE disease. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Kearon","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.cjca.2014.04.014_bib47","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1183\/09059180.00007309","article-title":"Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: pathophysiology","volume":"19","author":"Humbert","year":"2010","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.cjca.2014.04.014_bib48","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/j.jacc.2008.08.059","article-title":"Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial","volume":"52","author":"Jais","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2014.04.014_bib49","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1378\/chest.07-2681","article-title":"Long-term use of sildenafil in inoperable chronic thromboembolic pulmonary hypertension","volume":"134","author":"Suntharalingam","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.cjca.2014.04.014_bib50","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1378\/chest.128.4.2363","article-title":"Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension","volume":"128","author":"Hoeper","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.cjca.2014.04.014_bib51","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1136\/thx.2005.046961","article-title":"Bosentan in inoperable chronic thromboembolic pulmonary hypertension","volume":"60","author":"Hughes","year":"2005","journal-title":"Thorax"},{"key":"10.1016\/j.cjca.2014.04.014_bib52","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1183\/09031936.06.00135905","article-title":"The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study","volume":"28","author":"Hughes","year":"2006","journal-title":"Eur Respir J"},{"key":"10.1016\/j.cjca.2014.04.014_bib53","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1183\/09031936.00039007","article-title":"Long-term treatment with sildenafil in chronic thromboembolic pulmonary hypertension","volume":"30","author":"Reichenberger","year":"2007","journal-title":"Eur Respir J"},{"key":"10.1016\/j.cjca.2014.04.014_bib54","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1159\/000093322","article-title":"Long-term bosentan in chronic thromboembolic pulmonary hypertension","volume":"74","author":"Seyfarth","year":"2007","journal-title":"Respiration"},{"key":"10.1016\/j.cjca.2014.04.014_bib55","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1378\/chest.129.6.1636","article-title":"Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension","volume":"129","author":"Lang","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.cjca.2014.04.014_bib56","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1183\/09031936.01.17100080","article-title":"Long-term treatment of pulmonary hypertension with aerosolized iloprost","volume":"17","author":"Machherndl","year":"2001","journal-title":"Eur Respir J"},{"key":"10.1016\/j.cjca.2014.04.014_bib57","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa1209657","article-title":"Riociguat for the treatment of chronic thromboembolic pulmonary hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2014.04.014_bib58","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1161\/CIRCULATIONAHA.113.001458","article-title":"Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study","volume":"128","author":"Bonderman","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2014.04.014_bib59","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1183\/09031936.00213911","article-title":"Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial","volume":"41","author":"Hoeper","year":"2013","journal-title":"Eur Respir J"}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X14002803?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X14002803?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:38:10Z","timestamp":1760107090000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X14002803"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":59,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S0828282X14002803"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2014.04.014","relation":{},"ISSN":["0828-282X"],"issn-type":[{"value":"0828-282X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Riociguat: A Novel Therapeutic Option for Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjca.2014.04.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}